Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
B
Bert O'Neil, MD
Primary Investigator
Overview
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
Description
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Small Cell Lung Cancer,Soft Tissue Sarcoma,Diffuse Large B Cell Lymphoma,1802104579 (CPDR001XUS01)
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1802104579 (CPDR001XUS01)
